




## CV Template of KATRD International Conference 2021

<b>Name</b>	Naoko Aragane			
<b>First Name</b>	Naoko	<b>Last Name</b>	Aragane	
<b>Country</b>	Japan			
<b>Organization</b>	Saga University Hospital			
<b>Current Position</b>	Professor			

### Educational Background

Saga Medical School, M.D. 1987  
 Saga Medical School, Ph.D. 2000  
 Post-doctoral fellow 1997-1999  
 Department of Thoracic/Head and Neck Medical Oncology  
 University of Texas, M.D.Anderson Cancer Center  
 Houston, TX, U.S.A.

### Professional Experiences, Professional Organizations

Director 2017-present  
 Saga University Hospital Cancer Center

Professor 2015-present  
 Department of Respiratory Medicine, Saga University Hospital

Associate Professor 2010-present  
 Faculty of Medicine, Saga University

Assistant Professor 2003-2009  
 Faculty of Medicine, Saga University

Medical Instructor 2000-2003  
 Saga Medical School,

Researcher 1999-2000  
 Laboratory of Cancer Molecular Diagnosis and Gene Therapy  
 Saitama Cancer Center Research Institute  
 Saitama, Japan

Post-doctoral fellow 1997-1999  
 Department of Thoracic/Head and Neck Medical Oncology  
 University of Texas, M.D.Anderson Cancer Center  
 Houston, TX, U.S.A.

Research fellow 1994-1997  
 Saitama Cancer Center Research Institute



Saitama, Japan

Chest Physician  
Saga Medical School

1987-1994

## Main Scientific Publications

1. Sueoka-Aragane N, et al. The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment; *Cancer Med*, in press
2. Abe T, Nakashima C, Sato A, Harada Y, Sueoka E, Kimura S, Kawaguchi A, Sueoka-Aragane N. Origin of circulating free DNA in patients with lung cancer. *PLoS One*; 15: e0235611, 2020.
3. Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H. Multiplex gene-panel testing for lung cancer patients. *Pathol Int*. 2020
4. Komiya K, Nakamura T, Abe T, Ogusu S, Nakashima C, Takahashi K, Kimura S, Sueoka-Aragane N. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer. *Thorac Cancer*. 2019 10(9):1798-1804.
5. Nakamura T, Nakashima C, Komiya K, Kitera K, Hirai M, Kimura S, Aragane N. Mechanisms of acquired resistance to afatinib clarified with liquid biopsy. *PLoS One*. 2018 Dec 14;13(12):e0209384.
6. Uchibori K, Satouchi M, Sueoka-Aragane N, Urata Y, Sato A, Imamura F, Inoue T, Tachihara M, Kobayashi K, Katakami N, Kokan C, Hirashima T, Iwanaga K, Mori M, Aoe K, Morita S, Negoro S. Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. *Lung Cancer*. 2018;124:65-70.
7. Sato A, Nakashima C, Abe T, Kato J, Hirai M, Nakamura T, Komiya K, Kimura S, Sueoka E, Sueoka-Aragane N. Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy. *Oncotarget* 2018; 9:31904-31914.
8. Nakashima C, Sato A, Abe T, Kato J, Hirai M, Nakamura T, Komiya K, Sueoka E, Kimura S, Sueoka-Aragane N. Automated DNA extraction using cellulose magnetic beads can improve *EGFR* point mutation detection with liquid biopsy by efficiently recovering short and long DNA fragments. *Oncotarget*. 2018; 9:25181-25192.
9. Komiya K, Nakashima C, Nakamura T, Hirakawa H, Abe T, Ogusu S, Takahashi K, Takeda Y, Egashira Y, Kimura S, Sueoka-Aragane N. Current Status and Problems of T790M Detection, a Molecular Biomarker of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors, with Liquid Biopsy and Re-biopsy. *Anticancer Res*. 2018;38:3559-3566.
10. Nakamura T, Watanabe N, Sato A, Komiya K, Umeguchi H, Hosomi T, Hirai M, Sueoka E, Kimura S, Sueoka-Aragane N. Plasma T790M and HGF as potential predictive markers for EGFR-TKI re-challenge. *Oncol Lett*. 2017;13:4939-4946.
11. Sueoka-Aragane N, Katakami N, Satouchi M, Yokota S, Aoe K, Iwanaga K, Otsuka K, Morita S, Kimura S, Negoro S, For Hanshin-Saga Collaborative Cancer Study Group. Monitoring *EGFR* T790M with plasma DNA from lung cancer patients in a prospective observational study. 2016 *Cancer Sci* 107:162-7.



12. Sueoka-Aragane N, Sato A, Kobayashi N, Ide M, Yokoo M, Nagano Y, Sueoka E, Kimura S. Correlation between plasma DNA and tumor status in an animal model. PLoS One. 2014;9:e111881.
13. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Kobayashi N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012; 7:1369-1381.
14. Nakamura T, Sueoka-Aragane N, Iwanaga K, Sato A, Komiya K, Abe T, Ureshino N, Hayashi S, Hosomi T, Hirai M, Sueoka E, Kimura S. A non-invasive system for monitoring resistance to EGFR tyrosine kinase inhibitors with plasma DNA. J Thorac Oncol 6: 1639-1648, 2011.
15. Sueoka-Aragane N, Imai K, Komiya K, Sato A, Tomimasu R, Hisatomi T, Sakuragi T, Mitsuoka M, Hayashi S, Nakachi K, Sueoka E. Exon 19 of *EGFR* mutation in relation to the CA-repeat polymorphism in intron 1. Cancer Sci. 2008;99:1180-7
16. Sato A, Sueoka-Aragane N, Saitoh J, Komiya K, Hisatomi T, Tomimasu R, Hayashi S, Sueoka E. Establishment of a new method, transcription-reverse transcription concerted reaction, for detection of plasma *hnRNP B1* mRNA, a biomarker of lung cancer. J. Cancer Res. Clin. Oncol.2008;134:1191-7
17. Sueoka N, Sato A, Eguchi H, Komiya K, Sakuragi T, Mitsuoka M, Satoh T, Hayashi S, Nakachi K, Sueoka E. Mutation profile of *EGFR* gene detected by denaturing high-performance liquid chromatography in Japanese lung cancer patients. J. Cancer Res. Clin. Oncol. 133: 93-102, 2007.
18. Sueoka E, Sueoka N, Iwanaga K, Akemi, Suga K, Hayashi S, Nagasawa K, Nakachi K. Detection of plasma *hnRNP B1* mRNA, a new cancer biomarker, in lung cancer patients by quantitative real-time Polymerase Chain Reaction, Lung Cancer 48, 77-83, 2005.
19. Sueoka E., Sueoka N., Goto Y, Matsuyama S., Nishimura H., Sato M., Fujimura S., Chiba H., Fujiki H: *hnRNP B1* as early cancer biomarker for occult cancer of human lungs and bronchial dysplasia. Cancer Res. 61, 1896-1902, 2001
20. Sueoka N, Lee HY, Walsh GL, Hong WK, Kurie JM. Post-translational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-*trans* retinoic acid in human bronchial epithelial cells. Cancer Res. 59, 3838-3844, 1999
21. Sueoka N, Sueoka E, Miyazaki Y, Okabe S, Kurosumi M, Takayama S, Fujiki H. Molecular pathogenesis of interstitial pneumonitis with TNF- transgenic mice. Cytokine 10, 124-131, 1998
22. Sueoka E, Sueoka N, Kai Y, Okabe S, Suganuma M, Kanematsu K, Yamamoto T, Fujiki H. Anticancer activity of morphine and its synthetic derivative, KT 90, mediated through apoptosis and inhibition of NF-kB activation. Biochem. Biophys. Res. Comm. 252: 566-570, 1998.
23. Sueoka N, Sueoka E, Okabe S, Fuike H. Anti-cancer effects of morphine through inhibition of tumor necrosis factor- release and mRNA expression. Carcinogenesis, 17: 2337-2341, 1996.